Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion from the...
A PTC Therapeutics, Inc. anunciou hoje que a ANVISA (Agência Nacional de Vigilância Sanitária), a agência reguladora de medicamentos no Brasil,...
PTC Therapeutics, Inc. anunció hoy que la Agencia Nacional de Vigilancia Sanitaria de Brasil, ANVISA (Agência Nacional de Vigilância Sanitária),...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2022. "We are...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences: Cowen Virtual 42nd...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end...
A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que a Agência de Administração de Alimentos e Medicamentos dos EUA (FDA) concedeu análise...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha otorgado una...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE™ awards program for Duchenne muscular dystrophy...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del octavo programa anual de premios STRIVE™ para la distrofia muscular de Duchenne...
PTC Therapeutics, Inc. (NASDAQ: PTCT) a annoncé aujourd'hui le lancement du huitième programme annuel de prix STRIVE™ pour la dystrophie musculaire...
PTC Therapeutics, Inc. (NASDAQ: PTCT) ha anunciado hoy el lanzamiento del octavo programa anual de premios STRIVE™ para la distrofia muscular de...
A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do oitavo programa anual de premiação STRIVE™ para distrofia muscular de Duchenne...
PTC Therapeutics, Inc. (NASDAQ: PTCT) gab heute den Start des 8. jährlichen STRIVE™-Auszeichnungsprogramms für Duchenne-Muskeldystrophie (Duchenne)...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022, the company approved non-statutory stock options to purchase an aggregate ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) a annoncé aujourd'hui le lancement du 2022 Talent Pipeline Program de l'entreprise, une initiative mondiale...
A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do programa Global Talent Pipeline de 2022 da empresa, uma iniciativa global com...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.